APA (7th ed.) Citation

G, R., M, M., L, P., AM, C., A, C., P, P., & C, A. (2025). Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis. Advances in therapy, 42(2), 788. https://doi.org/10.1007/s12325-024-03000-x

Chicago Style (17th ed.) Citation

G, Rudofsky, Menzen M, Potier L, Catarig AM, Clark A, Priyadarshini P, and Abreu C. "Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis." Advances in Therapy 42, no. 2 (2025): 788. https://doi.org/10.1007/s12325-024-03000-x.

MLA (9th ed.) Citation

G, Rudofsky, et al. "Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis." Advances in Therapy, vol. 42, no. 2, 2025, p. 788, https://doi.org/10.1007/s12325-024-03000-x.